Plain-English translation of NCT05965479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an antibody-based medication designed to seek out and destroy cancer cells that have a specific protein called HER2. The study focuses on people with stomach cancer who have completed standard surgery and chemotherapy but still show traces of cancer in their bloodstream. Researchers hope this new treatment will prevent the cancer from coming back.
Currently, about half of people with stomach cancer treated with standard chemotherapy and surgery experience cancer recurrence. When traces of cancer remain in the bloodstream after standard treatment, additional standard chemotherapy often doesn't help. This trial exists to test whether the medication, which has shown promise in other HER2-positive cancers, might be more effective at eliminating these remaining cancer cells.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the medication through an IV infusion every three weeks for a total of eight cycles (about six months). Your first infusion will take about 90 minutes; subsequent infusions may be shorter if you tolerate the first one well. You will be followed closely with blood tests and imaging for up to two years to track how well the treatment works and monitor for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United Kingdom